demecolcine and Leukemia--Promyelocytic--Acute

The human promyelocytic leukaemia cell line HL-60 can be induced to differentiate towards mature granulocytes by treatment with dibutyryl cyclic adenosine-3',5'-monophosphate (dbcAMP). Differentiation begins within 16-24 h of treatment and is associated with a time- and dose-dependent accumulation of cells in the G0/G1 phase of the cell cycle with a concomitant decrease in the number of cells in the S and G2 + M phases. Using acridine orange staining, we found that the RNA content of the cells also decreased following differentiation. Stathmokinetic analysis of HL-60 cell populations following dbcAMP treatment showed no effect on the total number of cells in the G0/G1 or S phases, or the rate of progression of cells through these cell cycle compartments. In contrast, dbcAMP was found to induce a transient arrest of the cells in the G2 phase. We also found that differentiation induced by dbcAMP did not require progression of the cells through the cell cycle. Cells arrested in either G1/S by hydroxyurea or G2 + M by colcemid eventually expressed markers of mature granulocytes. These results demonstrate that dbcAMP modulates cell cycle progression. However, these cell cycle changes alone are insufficient to induce granulocytic differentiation of HL-60 cells.

Topics: Acridine Orange; Bucladesine; Cell Cycle; Cell Differentiation; Cell Line; Demecolcine; G2 Phase; Humans; Hydrogen Peroxide; Hydroxyurea; Kinetics; Leukemia, Promyelocytic, Acute; N-Formylmethionine Leucyl-Phenylalanine; Receptors, Formyl Peptide; Receptors, Immunologic; RNA, Neoplasm; Vinblastine